ilaprazole + aceclofenac

This is an **oral fixed-dose combination** of two active pharmaceutical ingredients: **ilaprazole**, a proton pump inhibitor (PPI), and **aceclofenac**, a nonsteroidal anti-inflammatory drug (NSAID). - **Aceclofenac** acts primarily by inhibiting cyclooxygenase (COX-2 > COX-1), thus reducing prostaglandin synthesis, pain, and inflammation. - **Ilaprazole** inhibits the gastric H+/K+-ATPase in parietal cells, thus suppressing gastric acid production and protecting the gastrointestinal mucosa. This combination is used to provide pain relief (from aceclofenac) and **reduce gastrointestinal side effects** and dyspepsia associated with NSAID therapy (by co-administering a PPI, ilaprazole). It has been studied in lumbar spinal stenosis patients with NSAID-induced dyspepsia, showing comparable efficacy and safety to celecoxib for these indications[1][3][5]. Aceclofenac is primarily indicated for musculoskeletal pain (osteoarthritis, rheumatoid arthritis, ankylosing spondylitis)[2][4], while ilaprazole is for acid-related gastrointestinal diseases such as gastroesophageal reflux and peptic ulcers[6].